* TRxADE Health Inc MEDS.OQ MEDS.O is expected to show a
fall
in quarterly revenue when it reports results on May 15.
* The Lutz Florida-based company is expected to report a
17.8% decrease in revenue to $2.663 million from $3.24 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for TRxADE Health Inc
is for
a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for TRxADE
Health Inc
is $1.7, above its last closing price of $0.38.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.06 -0.01 Beat 84.6
Sep. 30 2022 -0.12 -0.12 -0.06 Beat 50
Jun. 30 2022 -0.09 -0.10 -0.13 Missed -30
Mar. 31 2022 -0.11 -0.11 -0.12 Missed -5.9
Dec. -0.16 -0.15 -0.10 Beat 33.3
31 2021
Sep. 30 2021 -0.13 -0.13 -0.16 Missed -23.1
Jun. 30 2021 -0.09 -0.09 -0.17 Missed -96.1
Mar. 31 2021 -0.05 -0.05 -0.08 Missed -71.4
This summary was machine generated May 13 at 02:02 GMT. All
figures in US dollars unless otherwise stated